Corcept Therapeutics
CORT
205 hedge funds and large institutions have $1.08B invested in Corcept Therapeutics in 2019 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 70 increasing their positions, 66 reducing their positions, and 22 closing their positions.
70% more call options, than puts
Call options by funds: $10.2M | Put options by funds: $5.98M
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
6% more funds holding
Funds holding: 193 → 205 (+12)
3.06% more ownership
Funds ownership: 74.88% → 77.94% (+3.1%)
6% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 66
10% less capital invested
Capital invested by funds: $1.2B → $1.08B (-$126M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$19.7M |
| 2 |
Renaissance Technologies
New York
|
+$17.3M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$8.76M |
| 4 |
WG
Winton Group
London,
United Kingdom
|
+$8.29M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$7.44M |
Top Sellers
| 1 |
AAM
AMI Asset Management
Los Angeles,
California
|
-$11M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
-$9.71M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.11M |
| 4 |
Millennium Management
New York
|
-$3.41M |
| 5 |
MCM
Matarin Capital Management
New York
|
-$3.36M |
CORT Hedge Fund Activity: Q4 2019 in Review
205 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2019, worth a combined $1.08B — down 10% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CORT positions and 22 closed out — a net gain of 13 holders — while 70 added to existing stakes and 66 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $19.7M. The largest seller was AMI Asset Management, exiting entirely with an estimated $11M sold.
- 205 institutional investors held Corcept Therapeutics (CORT) as of Q4 2019, up from 193 in Q3 2019.
- Funds reported $1.08B of Corcept Therapeutics stock for Q4 2019, down 10% quarter-over-quarter.
- 35 funds opened new Corcept Therapeutics positions in Q4 2019 and 22 closed out, a net change of +13 holders.
- The largest Corcept Therapeutics buyer in Q4 2019 was Arrowstreet Capital, an estimated $19.7M added.
- The largest Corcept Therapeutics seller in Q4 2019 was AMI Asset Management, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2019.